SGLT2 inhibitors in Type 1 diabetes: is this the future?HYPOGLYCEMIADIABETIC acidosisTYPE 1 diabetesSODIUM-glucose cotransportersCOST effectivenessGLYCOSYLATED hemoglobinCANAGLIFLOZINDAPAGLIFLOZINEMPAGLIFLOZINGLYCEMIC controlDespite advances in insulin analogues and monitoring, and changes in insulin delivery, Type ...
"In our study, we have shown significant risk reductions for cardiovascular disease and kidney failure with SGLT2 inhibitor treatment in type 1 diabetes," said lead author Elisabeth Stougaard, Ph.D., of Steno Diabetes Center, in Copenhagen. "Our model provides an estimate of benefit that may b...
Cases of SGLT2 inhibitor-associated DKA have also beenpreviously reportedin patients with type 2 diabetes, and among patients with type 1 diabetes given the drugs off-label, as none of the drugs in the class are currently approved for treating type 1 diabetes. The US Food and Drug Administrat...
An updated recommendation advises that to lessen the risk of worsening heart failure and cardiovascular death, persons with diabetes and established heart failure with preserved or reduced ejection fraction undergo treatment with either an SGLT2 inhibitor or an SGLT1/2 inhibitor An updated recommendatio...
SGLT2 inhibitors are a new class of drug for the treatment of type 2 diabetes, but they are also being used off label in patients with type 1 diabetes. SUGGESTED for you One of the most concerning aspects of this euglycemic DKA is that patients do not realize it is happening: because gl...
The Invention relates to the Treatment or prevention of conditions one or more selected between diabetes mellitus Type 1, Type 2 diabetes, impaired glucose tolerance and hyperglycemia, using sglt-2 inhibitor. In addition, the present Invention relates to methods for preventing or treating Metabolic Di...
Type 1 and type 2 diabetes are characterized by chronic inflammation; both diseases involve pancreatic islet inflammation, while systemic low-grade inflammation is a feature of obesity and type 2 diabetes. Long-term activation of the innate immune system impairs insulin secretion and action, and infl...
57. Effect of Sodium-Glucose Cotransporter-2 Inhibitor on Blood Pressure in Patient with Type 2 Diabetes Mellitus with Renal Impairment: a Systematic Review Hypertension is a common comorbidity in patients with Type 2 Diabetes Mellitus (T2DM). One of the new anti-diabetic classes is (SGLT2) in...
A patient with pancreatogenic diabetes developed life-threatening euglycemic ketoacidosis following re-exposure to an SGLT2 inhibitor and alcohol excess. Early renal replacement therapy was successful. Use of GLP-1 agonists in...
Open Access Diabetes Case Study ICI-related diabetes developed after 18 months of nivolumab treatment for malignant melanoma. Diffusion-weighted imaging may provide valuable insights into pancreatic involvement at an early stage of the disease. SGLT2 inhibitor triggers metabolic encephalopathy Open Acces...